- Liproxstatin-1
-
- $77.00
-
2026-04-22
- CAS:950455-15-9
- Purity: 99.42%
- Supply Ability: 10g
- Liproxstatin-1
-
-
2026-02-02
- CAS:950455-15-9
- Min. Order: 5mg
- Purity: 99%
- Supply Ability: 2000tons
|
| | Liproxstatin-1 Basic information |
| Product Name: | Liproxstatin-1 | | Synonyms: | Liproxstatin-1;N-[(3-chlorophenyl)methyl]-spiro[piperidine-4,2'(1'H)-quinoxalin]-3'-amine;LIPROXSTATIN-1;LIPROXSTATIN1;CS-1656;N-[(3-chlorophenyl)methyl]spiro[4H-quinoxaline-3,4'-piperidine]-2-amine;Liproxstatin-1 USP/EP/BP;N-[(3-chlorophenyl)methyl]-1'H-spiro[piperidine-4,2'-quinoxaline]-3'-amine;Spiro[piperidine-4,2'(1'H)-quinoxalin]-3'-amine, N-[(3-chlorophenyl)methyl]- | | CAS: | 950455-15-9 | | MF: | C19H21ClN4 | | MW: | 340.85 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 950455-15-9.mol |  |
| | Liproxstatin-1 Chemical Properties |
| Boiling point | 581.4±50.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (15 mg/ml) | | form | powder | | pka | 9.45±0.40(Predicted) | | color | white to light brown | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 month. | | InChI | InChI=1S/C19H21ClN4/c20-15-5-3-4-14(12-15)13-22-18-19(8-10-21-11-9-19)24-17-7-2-1-6-16(17)23-18/h1-7,12,21,24H,8-11,13H2,(H,22,23) | | InChIKey | YAFQFNOUYXZVPZ-UHFFFAOYSA-N | | SMILES | N1CCC2(C(NCC3=CC=CC(Cl)=C3)=NC3=C(N2)C=CC=C3)CC1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Liproxstatin-1 Usage And Synthesis |
| Description | Liproxstatin-1 is a ferroptosis inhibitor. It inhibits ferroptotic cell death (IC50 = 22 nM) and lipid peroxidation in mouse embryonic fibroblasts (MEFs) with an inducible knockdown of glutathione peroxidase 4 (Gpx4-/- MEFs) when used at a concentration of 50 nM. Liproxstatin-1 also inhibits ferroptosis induced by the ferroptosis-inducing agents L-buthionine sulphoximine (BSO), erastin , and (1S,3R)-RSL3 in a concentration-dependent manner in MEFs, but does not inhibit necroptosis, apoptosis, or necrosis. It inhibits cell death and lipid peroxidation induced by (1S,3R)-RSL3 in human renal proximal tubule epithelial cells. Liproxstatin-1 (10 mg/kg) increases survival and decreases TUNEL+ kidney cells in inducible Gpx4-/- mice and reduces tissue injury in a mouse model of hepatic ischemia/reperfusion injury. It is also an antioxidant that inhibits autooxidation of lipids by trapping peroxyl radicals. | | Uses | Liproxstatin-1 has been used as a cell death inhibitor in the cell viability assay and for the determination of lipid peroxidation. | | Definition | ChEBI: Liproxstatin-1 is an azaspiro compound that is 1'H-spiro[piperidine-4,2'-quinoxaline] in which the hydrogen at position 3' is replaced by a (3-chlorobenzyl)amino group. It is a potent inhibitor of ferroptosis. It has a role as a ferroptosis inhibitor, a radical scavenger, an antioxidant and a cardioprotective agent. It is a member of monochlorobenzenes, a secondary amino compound, an azaspiro compound and an organic heterotricyclic compound. | | Biochem/physiol Actions | Liproxstatin-1 is a potent inhibitor of ferroptosis, a non-apoptotic form of cell death characterized by iron-dependent accumulation of lethal lipid reactive oxygen species (ROS). Liproxstatin-1 suppressed ferroptosis in human cells and in an ischaemia/reperfusion-induced tissue injury model in mice. Knockout of glutathione peroxidase 4 (Gpx4) Has been shown to cause cell death by ferroptosis. Liproxstatin-1 was able to suppress ferroptosis in Gpx4 knock-out mice. | | in vivo | Liproxstatin-1 (10 mg/kg, i.p.) suppresses ferroptosis in human cells, Gpx4 / kidney and in an ischaemia/reperfusion-induced tissue injury model[1]. | | References | [1] JOSE PEDRO FRIEDMANN ANGELI. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J]. Nature Cell Biology, 2014, 16 12: 1180-1191. DOI:10.1038/ncb3064
[2] YANSHENG FENG . Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels[J]. Biochemical and biophysical research communications, 2019, 520 3: Pages 606-611. DOI:10.1016/j.bbrc.2019.10.006
[3] OMKAR ZILKA. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death[J]. ACS Central Science, 2017, 3 3: 232-243. DOI:10.1021/acscentsci.7b00028 |
| | Liproxstatin-1 Preparation Products And Raw materials |
|